[
    {
        "pregunta": "1. What is the recommended treatment for adults with nonradiographic axial SpA who have active disease despite NSAID treatment?",
        "respuesta": "The recommended treatment for adults with nonradiographic axial spondyloarthritis (SpA) who continue to have active disease despite treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) includes:\n\n1. **Tumor Necrosis Factor Inhibitors (TNFi)**: There is a strong recommendation for the treatment with TNFi over no treatment with TNFi. This recommendation is based on high-quality evidence.\n\n2. **Sulfasalazine, Methotrexate, or Tofacitinib**: There is a conditional recommendation for treatment with these medications over no treatment with them, based on very low-quality evidence.\n\n3. **Secukinumab or Ixekizumab**: There is a conditional recommendation for treatment with secukinumab or ixekizumab over no treatment with these medications, based on very low-quality evidence.\n\nAdditionally, there is a conditional recommendation for treatment with TNFi over treatment with tofacitinib, also based on very low-quality evidence. No particular TNFi is recommended as the preferred choice.",
        "contexto": [
            "College of Rheumatology (ACR), Spondylitis Association of America (SAA), and Spondyloarthritis Research and Treatment Network (SPARTAN) published recommendations for the treatment of adults with AS and those with nonradiographic axial SpA The advent of new medications to treat axial SpA warranted this update. We did not reexamine all of the 2015 recommendations, but rather focused on those questions for which consequential new evidence was present. We added several new recommendations on how",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with sulfasalazine, methotrexate, or tofacitinib over no treatment with these medications.|Very low|39|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we strongly recommend treatment with TNFi over no treatment with TNFi.|High|38|\n|We do not recommend any particular TNFi as the preferred choice.|Very low|37|",
            "recommendation. Table 2 3 http:// onlin A. Recommendations for the treatment of patients with active AS In adults with active AS, we conditionally recommend continuous treatment with nonsteroidal antiinflammatory drugs (NSAIDs) over on-demand treatment with NSAIDs (PICO 1). The efficacy of NSAIDs for symptom improvement in active AS has been established in many controlled trials. Evidence that continuous NSAID use results in slower rates of spinal fusion on radiographs over 2 years compared to",
            "not using a treat-to-target strategy in patients in whom there are concerns related to increased adverse events, costs of therapy, and patient burden of medications associated with tighter control. Active PsA with psoriatic spondylitis/axial disease despite treatment with NSAIDs (Table 5). All recommendations for patients with active PsA with psoriatic spondylitis/ axial disease despite NSAID treatment are conditional based on very-low-quality evidence. The ACR/Spondylitis Association of",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with tofacitinib.|Very low|73|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over no treatment with secukinumab or ixekizumab.|Very low|71|"
        ]
    },
    {
        "pregunta": "2. When should treatment with TNFi be considered in adults with nonradiographic axial SpA?",
        "respuesta": "Treatment with tumor necrosis factor inhibitors (TNFi) should be considered in adults with nonradiographic axial spondyloarthritis (SpA) who have active disease despite treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). There is a strong recommendation for the treatment with TNFi over no treatment with TNFi based on high-quality evidence. Additionally, when considering other treatment options, there is a conditional recommendation for treatment with TNFi over treatment with tofacitinib and over treatment with secukinumab or ixekizumab, though these recommendations are based on very low-quality evidence.",
        "contexto": [
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with tofacitinib.|Very low|73|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over no treatment with secukinumab or ixekizumab.|Very low|71|",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with secukinumab or ixekizumab.|Very low|72|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with tofacitinib.|Very low|74|",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with sulfasalazine, methotrexate, or tofacitinib over no treatment with these medications.|Very low|39|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we strongly recommend treatment with TNFi over no treatment with TNFi.|High|38|\n|We do not recommend any particular TNFi as the preferred choice.|Very low|37|",
            "axial spondyloarthritis Parallel questions on pharmacologic treatment were investigated for patients with nonradiographic axial SpA. There were no relevant published data for 19 questions. There was high-quality evidence only for the use of TNFi in nonradiographic axial SpA, which was examined in several clinical trials. Low-quality or very low-quality evidence from single studies suggested no differences in outcomes among different TNFi in nonradiographic axial SpA, high likelihood of relapse",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs and who have contraindications to TNFi, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with sulfasalazine, methotrexate, or tofacitinib.|Very low|40|\n|In adults with active nonradiographic axial SpA and primary nonresponse to the first TNFi used, we conditionally recommend switching to secukinumab or ixekizumab over switching to a different TNFi.|Very low|42|"
        ]
    },
    {
        "pregunta": "3. What are the recommended medications for adults with active nonradiographic axial SpA who have contraindications to TNFi?",
        "respuesta": "For adults with active nonradiographic axial spondyloarthritis (SpA) who have contraindications to tumor necrosis factor inhibitors (TNFi), there is a conditional recommendation for treatment with secukinumab or ixekizumab over treatment with sulfasalazine, methotrexate, or tofacitinib. This recommendation is based on very low-quality evidence.",
        "contexto": [
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with sulfasalazine, methotrexate, or tofacitinib over no treatment with these medications.|Very low|39|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we strongly recommend treatment with TNFi over no treatment with TNFi.|High|38|\n|We do not recommend any particular TNFi as the preferred choice.|Very low|37|",
            "|In adults with active nonradiographic axial SpA despite treatment with the first TNFi used, we conditionally recommend against the addition of sulfasalazine or methotrexate in favor of treatment with a different biologic.|Very low|41|\n|We strongly recommend against treatment with systemic glucocorticoids.â€ |Very low|36|",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with tofacitinib.|Very low|73|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over no treatment with secukinumab or ixekizumab.|Very low|71|",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with secukinumab or ixekizumab.|Very low|72|\n|In adults with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with tofacitinib.|Very low|74|",
            "|In adults with active nonradiographic axial SpA despite treatment with NSAIDs and who have contraindications to TNFi, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with sulfasalazine, methotrexate, or tofacitinib.|Very low|40|\n|In adults with active nonradiographic axial SpA and primary nonresponse to the first TNFi used, we conditionally recommend switching to secukinumab or ixekizumab over switching to a different TNFi.|Very low|42|"
        ]
    },
    {
        "pregunta": "4. In adults with isolated active sacroiliitis despite NSAID treatment, what is the recommended approach for glucocorticoid treatment?",
        "respuesta": "The recommended approach for glucocorticoid treatment in adults with isolated active sacroiliitis who continue to have active disease despite treatment with NSAIDs is to use locally administered parenteral glucocorticoids. There is a conditional recommendation for this approach over no treatment with local glucocorticoids, based on very low-quality evidence.",
        "contexto": [
            "|In adults with isolated active sacroiliitis despite treatment with NSAIDs, we conditionally recommend treatment with local glucocorticoids over no treatment with local glucocorticoids.â€ |Very low|45|",
            "|16. In adults with isolated active sacroiliitis despite treatment with NSAIDs, we conditionally recommend treatment with locally administered parenteral glucocorticoids over no treatment with local glucocorticoids.â€ |Very low|13|",
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "|18. In adults with stable axial disease and active peripheral arthritis despite treatment with NSAIDs, we conditionally recommend using treatment with locally administered parenteral glucocorticoids over no treatment with local glucocorticoids.â€ |Very low|15|\n|19. We strongly recommend treatment with physical therapy over no treatment with physical therapy.â€ |Moderate|16|",
            "|17. In adults with stable axial disease and active enthesitis despite treatment with NSAIDs, we conditionally recommend using treatment with locally administered parenteral glucocorticoids over no treatment with local glucocorticoids. Peri-tendon injections of Achilles, patellar, and quadriceps tendons should be avoided.â€ |Very low|14|"
        ]
    },
    {
        "pregunta": "5. What is the recommendation regarding physical therapy for adults with nonradiographic axial SpA?",
        "respuesta": "The information provided does not include a specific recommendation regarding physical therapy for adults with nonradiographic axial spondyloarthritis (SpA). Therefore, it is not possible to provide a recommendation based on the given data.",
        "contexto": [
            "College of Rheumatology (ACR), Spondylitis Association of America (SAA), and Spondyloarthritis Research and Treatment Network (SPARTAN) published recommendations for the treatment of adults with AS and those with nonradiographic axial SpA The advent of new medications to treat axial SpA warranted this update. We did not reexamine all of the 2015 recommendations, but rather focused on those questions for which consequential new evidence was present. We added several new recommendations on how",
            "<hr />\n\n<h1>Table 3. Recommendations for the treatment of adults with nonradiographic axial SpA*</h1>",
            "new evidence was present. We added several new recommendations on how the newly available medications should fit in treatment strategies and on the use of imaging. The target populations are adults with AS or nonradiographic axial SpA. The target users of these recommendations are rheumatologists, primary care clinicians, physiatrists, physical therapists, and others providing care to patients with axial SpA. METHODS These recommendations followed ACR and Grading of Recommendations, Assessment,",
            "|83. In adults with active nonradiographic axial SpA, we conditionally recommend against using a treat-to-target strategy using a target of ASDAS &lt;1.3 (or 2.1) over a treatment strategy based on physician assessment.|Very low|80|\n|84. In adults with nonradiographic axial SpA of unclear activity while on a biologic, we conditionally recommend obtaining a pelvis MRI to assess activity.|Very low|81|",
            "|85. In adults with stable nonradiographic axial SpA, we conditionally recommend against obtaining a spinal or pelvis MRI to confirm inactivity.|Very low|82|\n|86. In adults with active or stable nonradiographic axial SpA on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach.|Very low|83|</p>"
        ]
    },
    {
        "pregunta": "6. When should treatment with biologics be discontinued in adults with nonradiographic axial SpA?",
        "respuesta": "The provided information does not include specific recommendations on when to discontinue treatment with biologics in adults with nonradiographic axial spondyloarthritis (SpA). However, it does mention that discontinuation of biologics is not recommended due to the likelihood of symptom recurrence. Thus, based on the available data, discontinuation of biologics in adults with nonradiographic axial SpA is generally not advised.",
        "contexto": [
            "|In adults with active nonradiographic axial SpA despite treatment with the first TNFi used, we conditionally recommend against the addition of sulfasalazine or methotrexate in favor of treatment with a different biologic.|Very low|41|\n|We strongly recommend against treatment with systemic glucocorticoids.â€ |Very low|36|",
            "|In adults with active nonradiographic axial SpA and secondary nonresponse to the first TNFi used, we conditionally recommend switching to a different TNFi over switching to a non-TNFi biologic.|Very low|42|\n|In adults with active nonradiographic axial SpA despite treatment with the first TNFi used, we strongly recommend against switching to the biosimilar of the first TNFi.|Very low|75|",
            "College of Rheumatology (ACR), Spondylitis Association of America (SAA), and Spondyloarthritis Research and Treatment Network (SPARTAN) published recommendations for the treatment of adults with AS and those with nonradiographic axial SpA The advent of new medications to treat axial SpA warranted this update. We did not reexamine all of the 2015 recommendations, but rather focused on those questions for which consequential new evidence was present. We added several new recommendations on how",
            "coexisting IBD, the update includes a conditional recommendation for TNFi monoclonal antibodies over other biologics, rather than over only etanercept. Finally, the recommendation for use of TNFi in patients with active nonradiographic axial SpA was changed from conditional to strong. New questions on the treatment of patients with stable disease were addressed in this update. Discontinuation of biologics is not recommended due to the likelihood for symptom recurrence. If tapering is",
            "|83. In adults with active nonradiographic axial SpA, we conditionally recommend against using a treat-to-target strategy using a target of ASDAS &lt;1.3 (or 2.1) over a treatment strategy based on physician assessment.|Very low|80|\n|84. In adults with nonradiographic axial SpA of unclear activity while on a biologic, we conditionally recommend obtaining a pelvis MRI to assess activity.|Very low|81|"
        ]
    },
    {
        "pregunta": "7. What is the recommendation regarding the use of CRP concentrations or ESR monitoring in adults with nonradiographic axial SpA?",
        "respuesta": "The recommendation regarding the use of C-reactive protein (CRP) concentrations or erythrocyte sedimentation rate (ESR) monitoring in adults with nonradiographic axial spondyloarthritis (SpA) is to conditionally recommend the regular-interval use and monitoring of CRP concentrations or ESR over usual care without regular monitoring. This recommendation is based on very low-quality evidence.",
        "contexto": [
            "|43. We conditionally recommend regular-interval use and monitoring of CRP concentrations or ESR over usual care without regular CRP or ESR monitoring.â€ |Very low|55|\n|44. In adults with active AS, we conditionally recommend against using a treat-to-target strategy using a target of ASDAS &lt;1.3 (or 2.1) over a treatment strategy based on physician assessment.|Low|67|\n|45. We conditionally recommend screening for osteopenia/osteoporosis with DXA scan over no screening.â€ |Very low|49|",
            "ESR = erythrocyte sedimentation rate; ASDAS = Ankylosing Spondylitis Disease Activity Score; DXA = dual x-ray absorptiometry; MRI = magnetic resonance imaging. â€  These recommendations were from 2015 and were not reviewed in this update. The number preceding the recommendation is the recommendation number and is referenced as bracketed numbers in Figure 1 uncertainty regarding potential disease-modifying effects, the committee conditionally favored continuous use of NSAIDs in patients with",
            "values and preferences. In adults with active or stable AS on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach. Very low * AS = ankylosing spondylitis; PICO = population, intervention, comparison, and outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; TNFi = tumor necrosis factor inhibitor; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ASDAS = Ankylosing Spondylitis",
            "College of Rheumatology (ACR), Spondylitis Association of America (SAA), and Spondyloarthritis Research and Treatment Network (SPARTAN) published recommendations for the treatment of adults with AS and those with nonradiographic axial SpA The advent of new medications to treat axial SpA warranted this update. We did not reexamine all of the 2015 recommendations, but rather focused on those questions for which consequential new evidence was present. We added several new recommendations on how",
            "expressed by the ACR Imaging remains a central tool in the diagnosis of axial SpA, but its role in monitoring patients is less well-defined. Spine and/or pelvis MRI could aid in the evaluation of patients in whom the degree of active inflammation is uncertain, and especially in those for whom the findings would change management. MRI is not recommended to seek subclinical inflammation in patients with stable disease (as defined in Table 1 We used the GRADE method to develop these treatment"
        ]
    },
    {
        "pregunta": "8. What is the recommended approach for assessing disease activity in adults with nonradiographic axial SpA?",
        "respuesta": "The recommended approach for assessing disease activity in adults with nonradiographic axial spondyloarthritis (SpA) is to rely on physician assessment rather than a treat-to-target strategy using a target of Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 (or 2.1). There is a conditional recommendation against using the treat-to-target strategy, as it is based on very low-quality evidence. Additionally, in cases where the activity of nonradiographic axial SpA is unclear while on a biologic, there is a conditional recommendation to obtain a pelvis MRI to assess activity. This is also based on very low-quality evidence and is intended to provide further clarity on disease activity when physical and laboratory measures may not adequately indicate ongoing inflammation.",
        "contexto": [
            "College of Rheumatology (ACR), Spondylitis Association of America (SAA), and Spondyloarthritis Research and Treatment Network (SPARTAN) published recommendations for the treatment of adults with AS and those with nonradiographic axial SpA The advent of new medications to treat axial SpA warranted this update. We did not reexamine all of the 2015 recommendations, but rather focused on those questions for which consequential new evidence was present. We added several new recommendations on how",
            "|83. In adults with active nonradiographic axial SpA, we conditionally recommend against using a treat-to-target strategy using a target of ASDAS &lt;1.3 (or 2.1) over a treatment strategy based on physician assessment.|Very low|80|\n|84. In adults with nonradiographic axial SpA of unclear activity while on a biologic, we conditionally recommend obtaining a pelvis MRI to assess activity.|Very low|81|",
            "3 E. Disease activity assessment and imaging In adults with active AS, we conditionally recommend against using the treat-to-target strategy, which aims at a target of an Ankylosing Spondylitis Disease Activity Score <1.3 (or 2.1), over a treatment strategy based on physician assessment (new, PICO 67). The concept of treat-to-target strategies is well-founded in chronic disease management for conditions that have an accurate measure of disease activity (often one that is asymptomatic, as in",
            "a spinal or pelvis MRI to assess activity (new, PICO 68). In adults with nonradiographic axial SpA of unclear activity while receiving a biologic, we conditionally recommend obtaining a pelvis MRI to assess activity (new, PICO 81). Because physical and laboratory measures are often normal despite active axial SpA, and because symptoms may be nonspecific, it may be difficult to know whether a patient is experiencing inflammation that warrants a change in treatment. Limited evidence suggests that",
            "|85. In adults with stable nonradiographic axial SpA, we conditionally recommend against obtaining a spinal or pelvis MRI to confirm inactivity.|Very low|82|\n|86. In adults with active or stable nonradiographic axial SpA on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach.|Very low|83|</p>"
        ]
    },
    {
        "pregunta": "9. In adults with nonradiographic axial SpA of unclear activity while on a biologic, what imaging study is recommended?",
        "respuesta": "For adults with nonradiographic axial spondyloarthritis (SpA) whose disease activity is unclear while being treated with a biologic, the recommended imaging study is a pelvis MRI. This recommendation is based on very low-quality evidence and is suggested because physical and laboratory measures often may not adequately reflect active inflammation, and symptoms can be nonspecific.",
        "contexto": [
            "a spinal or pelvis MRI to assess activity (new, PICO 68). In adults with nonradiographic axial SpA of unclear activity while receiving a biologic, we conditionally recommend obtaining a pelvis MRI to assess activity (new, PICO 81). Because physical and laboratory measures are often normal despite active axial SpA, and because symptoms may be nonspecific, it may be difficult to know whether a patient is experiencing inflammation that warrants a change in treatment. Limited evidence suggests that",
            "|83. In adults with active nonradiographic axial SpA, we conditionally recommend against using a treat-to-target strategy using a target of ASDAS &lt;1.3 (or 2.1) over a treatment strategy based on physician assessment.|Very low|80|\n|84. In adults with nonradiographic axial SpA of unclear activity while on a biologic, we conditionally recommend obtaining a pelvis MRI to assess activity.|Very low|81|",
            "|85. In adults with stable nonradiographic axial SpA, we conditionally recommend against obtaining a spinal or pelvis MRI to confirm inactivity.|Very low|82|\n|86. In adults with active or stable nonradiographic axial SpA on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach.|Very low|83|</p>",
            "with stable AS, we conditionally recommend against obtaining a spinal or pelvis MRI to confirm inactivity (new, PICO 69). In adults with stable nonradiographic axial SpA, we conditionally recommend against obtaining a spine or pelvis MRI to confirm inactivity (new, PICO 82). Because the clinical assessment of inflammation in axial SpA has many limitations, questions may arise about whether subclinical inflammation that could be detected by MRI is being \"missed\" by either the physical",
            "College of Rheumatology (ACR), Spondylitis Association of America (SAA), and Spondyloarthritis Research and Treatment Network (SPARTAN) published recommendations for the treatment of adults with AS and those with nonradiographic axial SpA The advent of new medications to treat axial SpA warranted this update. We did not reexamine all of the 2015 recommendations, but rather focused on those questions for which consequential new evidence was present. We added several new recommendations on how"
        ]
    },
    {
        "pregunta": "10. What is the recommended approach for obtaining repeat spine radiographs in adults with active or stable nonradiographic axial SpA?",
        "respuesta": "The recommended approach for obtaining repeat spine radiographs in adults with active or stable nonradiographic axial spondyloarthritis (SpA) is to conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach. This recommendation is based on very low-quality evidence.",
        "contexto": [
            "|85. In adults with stable nonradiographic axial SpA, we conditionally recommend against obtaining a spinal or pelvis MRI to confirm inactivity.|Very low|82|\n|86. In adults with active or stable nonradiographic axial SpA on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach.|Very low|83|</p>",
            "obtaining an MRI in this setting. MRI could be considered in circumstances where the clinician and patient differ in their assessment of whether the disease is stable. In adults with active or stable AS receiving any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach (new, PICO 70). In adults with active or stable nonradiographic axial SpA on any treatment, we conditionally recommend against",
            "axial SpA on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach (new, PICO 83). Spine radiographs are useful for the diagnosis of axial SpA, in evaluating the extent of spinal fusion, and for investigating new spinal pain in patients with established AS. In research studies, small changes in the extent of spine damage can be detected in 20-35% of patients with AS over a 2-year interval (see",
            "|51. In adults with active or stable AS on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach.|Very low|70|</p>",
            "values and preferences. In adults with active or stable AS on any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach. Very low * AS = ankylosing spondylitis; PICO = population, intervention, comparison, and outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; TNFi = tumor necrosis factor inhibitor; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ASDAS = Ankylosing Spondylitis"
        ]
    }
]